Sudeep Pharma IPO Soars on Debut, Investors Gain 24% on First Day

Mumbai: Pharmaceutical company Sudeep Pharma made a spectacular debut on the stock market on Friday, rewarding its IPO investors with handsome gains. Shares listed at a significant premium, reflecting strong investor enthusiasm.

On the BSE, the stock opened at ₹733.95 per share against its issue price of ₹593, marking a 23.77% gain. Meanwhile, on the NSE, it started at ₹730, up 23.10% from the issue price. This listing largely met expectations set by the grey market premium (GMP), which was around 20% prior to listing.

Strong Investor Response
Sudeep Pharma’s IPO witnessed overwhelming demand. Open for subscription from 21 to 25 November, the IPO was subscribed 93.71 times overall. Qualified Institutional Buyers (QIBs) bid 213.08 times, marking one of the most aggressively sought entries in the chemicals and ingredients sector this year. High Net-Worth Individuals (HNIs) subscribed 116.72 times, while retail investors applied 15.65 times for their allotted quota. During the anchor allocation round on 20 November, the company raised ₹268.50 crore by allotting 45.27 lakh shares. The first tranche of anchor lock-in will end on 26 December.

Pricing Details
The IPO had a price band of ₹563–593, with the final issue price set at the upper band of ₹593. Based on GMP, the listing was expected between ₹700–720. Market sentiment and sectoral performance in mid-caps and specialty chemicals will influence its further price movements.

About Sudeep Pharma
Sudeep Pharma is a leading manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, supplying over 100 countries. The company operates six manufacturing plants with a total capacity of 50,000 tonnes, producing mineral-based ingredients for pharma, nutraceuticals, food processing, and specialty nutrition products. Its portfolio includes more than 200 products, such as calcium, magnesium, iron, potassium, zinc, sodium, triturates, and high-value excipients used by global pharmaceutical firms.

Financial Performance
Sudeep Pharma has demonstrated consistent growth over the past three fiscal years. FY24 revenue of ₹465.38 crore increased to ₹511.33 crore in FY25, a 10% growth, while net profit rose from ₹133.15 crore to ₹138.69 crore. For the June 2025 quarter, revenue was ₹130.08 crore, with a profit of ₹31.27 crore. FY25 EBITDA stood at ₹199.28 crore, showing a margin of 39.70%, and PAT margin was 27.63%, reflecting robust fundamentals and operational efficiency. The balance sheet is strong, with a debt-to-equity ratio of 0.20 and reserves of ₹668.52 crore as of FY25.

Sudeep Pharma’s IPO listing has set a strong tone for the pharmaceutical and specialty chemicals sector, rewarding investors on the very first day.